RECRUITINGPhase 2INTERVENTIONAL
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease
About This Trial
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Who May Be Eligible (Plain English)
Who May Qualify:
- Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
- Ability to provide written willing to sign a consent form
- Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
- Negative urine pregnancy test for anyone of childbearing potential at study entry
Who Should NOT Join This Trial:
- Pregnant women
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Hospitalizations (for any cause) within 2 weeks of study entry
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
* Ability to provide written informed consent
* Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
* Negative urine pregnancy test for anyone of childbearing potential at study entry
Exclusion Criteria:
* Pregnant women
* Adults unable to consent
* Individuals who are not yet adults (infants, children, teenagers)
* Prisoners
* Hospitalizations (for any cause) within 2 weeks of study entry
Treatments Being Tested
DRUG
Alendronate Sodium
Administer oral alendronate 70 mg once a week x 24 weeks to all study participants
Locations (1)
UC Davis Comprehensive Cancer Center
Sacramento, California, United States